Liver organoids: from basic research to therapeutic applications

Prior, Nicole; Inácio, Patrícia; Huch, Meritxell

doi:10.1136/gutjnl-2019-319256

Cited by 258 publications

(222 citation statements)

References 114 publications

(150 reference statements)

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…Our approach is applicable to any inherited disease, both WGS and RNA-seq techniques are commercially available, gold standards are being established and the analysis tools are readily accessible 47, 48, 49–55, 81, 82 . Ex vivo organoid models are being developed for a multitude of tissues including brain 83, 84 , kidney 85 , liver 86, 87 and lung 88 .…”

Section: Discussionmentioning

confidence: 99%

A combined RNA-seq and whole genome sequencing approach for identification of non-coding pathogenic variants in single families

Bronstein

Capowski

Mehrotra

et al. 2019

Preprint

View full text Add to dashboard Cite

Inherited retinal degenerations (IRDs) are at the focus of current genetic therapeutic advancements. For a genetic treatment such as gene therapy to be successful an accurate genetic diagnostic is required. Genetic diagnostics relies on the assessment of the probability that a given DNA variant is pathogenic. Non-coding variants present a unique challenge for such assessments as compared to coding variants. For one, non-coding variants are present at much higher number in the genome than coding variants. In addition, our understanding of the rules that govern the non-coding regions of the genome is less complete than our understanding of the coding regions. Methods that allow for both the identification of candidate non-coding pathogenic variants and their functional validation may help overcome these caveats allowing for a greater number of patients to benefit from advancements in genetic therapeutics. We present here an unbiased approach combining whole genome sequencing (WGS) with patient induced pluripotent stem cell (iPSC) derived retinal organoids (ROs) transcriptome analysis. With this approach we identified and functionally validated a novel pathogenic non-coding variant in a small family with a previously unresolved genetic diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

A combined RNA-seq and whole genome sequencing approach for identification of non-coding pathogenic variants in single families

Bronstein

Capowski

Mehrotra

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Combining organoid cultivation with organ chips can better control the organoids and their growth microenvironment, and strengthen the interaction between tissues and multiple organs. The research in this area is still ongoing [75].…”

Section: Research Progress Of Liver Chips For Drug Toxicity Testingmentioning

confidence: 99%

Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review

et al. 2020

View full text Add to dashboard Cite

Organ-on-a-chip academic research is in its blossom. Drug toxicity evaluation is a promising area in which organ-on-a-chip technology can apply. A unique advantage of organ-on-a-chip is the ability to integrate drug metabolism and drug toxic processes in a single device, which facilitates evaluation of toxicity of drug metabolites. Human organ-on-a-chip has been fabricated and used to assess drug toxicity with data correlation with the clinical trial. In this review, we introduced the microfluidic chip models of liver, kidney, heart, nerve, and other organs and multiple organs, highlighting the application of these models in drug toxicity detection. Some biomarkers of toxic injury that have been used in organ chip platforms or have potential for use on organ chip platforms are summarized. Finally, we discussed the goals and future directions for drug toxicity evaluation based on organ-on-a-chip technology.

show abstract

“…[221] However, despite the great advances that have been made on this model, there are limitation for the use of liver organoids in biomedical applications due to the lack of control on cell com position, structure and size. [222][223][224] More examples of advanced processing technologies appli cations, including the cell types and biomaterials used, can be found in Table 3.…”

Section: Liver Organoidsmentioning

confidence: 99%

Advanced Biomaterials and Processing Methods for Liver Regeneration: State‐of‐the‐Art and Future Trends

Morais

Vieira

Zhao

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Liver diseases contribute markedly to the global burden of mortality and disease. The limited organ disposal for orthotopic liver transplantation results in a continuing need for alternative strategies. Over the past years, important progress has been made in the field of tissue engineering (TE). Many of the early trials to improve the development of an engineered tissue construct are based on seeding cells onto biomaterial scaffolds. Nowadays, several TE approaches have been developed and are applied to one vital organ: the liver. Essential elements must be considered in liver TE—cells and culturing systems, bioactive agents or growth factors (GF), and biomaterials and processing methods. The potential of hepatocytes, mesenchymal stem cells, and others as cell sources is demonstrated. They need engineered biomaterial‐based scaffolds with perfect biocompatibility and bioactivity to support cell proliferation and hepatic differentiation as well as allowing extracellular matrix deposition and vascularization. Moreover, they require a microenvironment provided using conventional or advanced processing technologies in order to supply oxygen, nutrients, and GF. Herein the biomaterials and the conventional and advanced processing technologies, including cell‐sheets process, 3D bioprinting, and microfluidic systems, as well as the future trends in these major fields are discussed.

show abstract

Liver organoids: from basic research to therapeutic applications

Cited by 258 publications

References 114 publications

A combined RNA-seq and whole genome sequencing approach for identification of non-coding pathogenic variants in single families

A combined RNA-seq and whole genome sequencing approach for identification of non-coding pathogenic variants in single families

Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review

Advanced Biomaterials and Processing Methods for Liver Regeneration: State‐of‐the‐Art and Future Trends

Contact Info

Product

Resources

About